-
Mashup Score: 1ROTEM in Trauma: Blood is thicker with Wine - Part 2 - 29 day(s) ago
Ever wondered how to read a TEG/ROTEM output in a bleeding trauma patient? Dr. Richard Hoang breaks it down into easy-to-follow steps.
Source: emottawablog.comCategories: General Medicine NewsTweet
-
Mashup Score: 6Essential Thrombocythemia with Dr. Raajit Rampal - 2 month(s) ago
In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes:1. IPSET (revised) s…
Source: www.youtube.comCategories: General Medicine NewsTweet-
World-class insights on Essential Thrombocythemia from Dr. @RaajitRampal. A must-watch for anyone seeking expert knowledge on ET! Check it out: https://t.co/q4WlnBg9YY #EssentialThrombocythemia #MedTwitter @AshKishtagari @rajshekharucms
-
-
Mashup Score: 2Evaluation of MIR-371A-3P for clinical implementation in a CLIA-certified laboratory. - 3 month(s) ago
648Background: MicroRNAs (mi-RNAs) have emerged as promising biomarkers for the detection of viable germ cell tumors (GCT). Our previous work in a research lab demonstrated optimal performance with positive results that had Cq values less than 28, an …
Source: ascopubs.orgCategories: General Medicine News, Expert PicksTweet-
MIR-371A-3P in GCT. #onctwitter #MedTwitter https://t.co/rNpNW7IZtD
-
-
Mashup Score: 10Review: Essential Thrombocythemia - 4 month(s) ago
This narrative review summarizes current evidence on the pathophysiology, clinical presentation and diagnosis, risk stratification, and treatment of essential thrombocythemia.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
RT @UsuarezMD: Essential Thrombocythemia: A Review | Hematology | JAMA | JAMA Network https://t.co/HbUjCW40UQ
-
-
Mashup Score: 10Review: Essential Thrombocythemia - 5 month(s) ago
This narrative review summarizes current evidence on the pathophysiology, clinical presentation and diagnosis, risk stratification, and treatment of essential thrombocythemia.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
RT @UsuarezMD: Essential Thrombocythemia: A Review | Hematology | JAMA | JAMA Network https://t.co/HbUjCW40UQ
-
-
Mashup Score: 10Review: Essential Thrombocythemia - 5 month(s) ago
This narrative review summarizes current evidence on the pathophysiology, clinical presentation and diagnosis, risk stratification, and treatment of essential thrombocythemia.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
RT @UsuarezMD: Essential Thrombocythemia: A Review | Hematology | JAMA | JAMA Network https://t.co/HbUjCW40UQ
-
-
Mashup Score: 26
In Volume 3 of his series, Dr. Dawood Findakly provides guidance on the virtual fellowship interview process.
Source: connection.asco.orgCategories: General Medicine News, Hem/OncsTweet-
🌟The Fellowship interviews are underway! The key is to be yourself and show genuine interest during the interview. Good luck to everyone! For more tips, check out 👉https://t.co/PscgNO8eLL @ASCO @HemOncFellows @ASCOTECAG #MedTwitter
-
-
Mashup Score: 1FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer - 9 month(s) ago
The FDA approved adjuvant ribociclib plus a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
RT @OncLive: BREAKING: @US_FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer #bcsm #oncology https://t.co/WjY32RM9kc https://t.co…
-
-
Mashup Score: 1FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer - 9 month(s) ago
The FDA approved adjuvant ribociclib plus a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
RT @OncLive: BREAKING: @US_FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer #bcsm #oncology https://t.co/WjY32RM9kc https://t.co…
-
-
Mashup Score: 1FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer - 9 month(s) ago
The FDA approved adjuvant ribociclib plus a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
RT @OncLive: BREAKING: @US_FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer #bcsm #oncology https://t.co/WjY32RM9kc https://t.co…
-
Managing major #bleeding utilizing thromboelastometry/thromboelastography #ROTEM #TEG #MedTwitter https://t.co/Ss4VHEStSf https://t.co/mA0YBvRECY